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ttp://dx.doi.org/10.1016/j.ajpath.2012.11.017Patients with neuroﬁbromatosis type 1 (NF1) develop benign plexiformneuroﬁbromas that frequently progress
to become malignant peripheral nerve sheath tumors (MPNSTs). A genetically engineered mouse model that
accurately models plexiform neuroﬁbromaeMPNST progression in humans would facilitate identiﬁcation of
somaticmutations driving this process.We previously reported that transgenicmice overexpressing the growth
factor neuregulin-1 in Schwann cells (P0-GGFb3 mice) develop MPNSTs. To determine whether P0-GGFb3 mice
accurately model human neuroﬁbromaeMPNST progression, cohorts of these animals weremonitored through
death and were necropsied; 94% developed multiple neuroﬁbromas, with 70% carrying smaller numbers of
MPNSTs. Nascent MPNSTs were identiﬁed within neuroﬁbromas, suggesting that these sarcomas arise
from neuroﬁbromas. Although neuroﬁbromin expression was maintained, P0-GGFb3 MPNSTs exhibited Ras
hyperactivation, as in human NF1-associated MPNSTs. P0-GGFb3 MPNSTs also exhibited abnormalities in the
p16INK4Aecyclin D/CDK4eRb and p19ARFeMdmep53 pathways, analogous to their human counterparts. Array
comparative genomic hybridization (CGH) demonstrated reproducible chromosomal alterations in P0-GGFb3
MPNST cells (including universal chromosome 11 gains) and focal gains and losses affecting 39 neoplasia-
associated genes (including Pten, Tpd52, Myc, Gli1, Xiap, and Bbc3/PUMA). Array comparative genomic
hybridization also identiﬁed recurrent focal copy number variations affecting genes not previously linked to
neuroﬁbroma or MPNST pathogenesis. We conclude that P0-GGFb3 mice represent a robust model of
neuroﬁbroma-MPNST progression useful for identifying novel genes driving neuroﬁbroma and MPNST patho-
genesis. (Am J Pathol 2013, 182: 646e667; http://dx.doi.org/10.1016/j.ajpath.2012.11.017)Supported by the NIH National Cancer Institute grants R01 CA122804
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peer review process or ﬁnal disposition for this article.Malignant peripheral nerve sheath tumors (MPNSTs) are
highly aggressive Schwann cellederived sarcomas. Although
MPNSTs occur both sporadically and in individuals with
neuroﬁbromatosis type 1 (NF1),1e5 our current understanding
ofMPNSTpathogenesis is derived largely from studies ofNF1-
associated MPNSTs. In NF1, MPNSTs arise from plexiform
neuroﬁbromas, which are benign tumors of peripheral nerve
composed of NF1-null Schwann-like cells intermingled with
NF1þ/ mast cells, perineurial-like cells, and ﬁbroblasts. The
initiating event in plexiform neuroﬁbroma pathogenesis is
thought to be the loss of the remaining functional NF1 allele in
an NF1þ/ cell in the Schwann cell lineage. This loss sets into
motion a complex series of changes, including enhancedstigative Pathology.
.production of growth factors that recruit the other NF1þ/ cell
types into the nascent neuroﬁbroma. The subsequent mutation
Mouse Model of NFeMPNST Progressionof additional tumor suppressor genes such as TP53, CDKN2A,
and PTEN in the NF1/ Schwann-like cells promotes malig-
nant transformation and MPNST pathogenesis.6,7
The scenario outlined above is conceptually attractive and
widely accepted. Nonetheless, there are several reasons to think
that it is incomplete and understates the genomic diversity of
plexiform neuroﬁbromas and MPNSTs. For instance, speciﬁc
genomic gains and losses affecting multiple chromosomes are
common in neuroﬁbromas,8,9 raising the question of whether
additional somatic mutations act cooperatively with NF1 loss to
promote neuroﬁbroma pathogenesis. In addition, at least some
sporadic MPNSTs lack NF1 mutations,10 indicating that these
sarcomas can arise via genetic pathways that do not involveNF1
loss. There is also evidence suggesting that the pathways
involved in neuroﬁbromaeMPNST progression are heteroge-
neous. As an example, although it was initially reported that
TP53wasmutated in a veryhighpercentageofMPNSTs,11more
recentﬁndingsargue that onlyaminorityofMPNSTscarryTP53
mutations.12,13 There is also reason to think that other genes, in
addition to those noted above, promote neuroﬁbromaeMPNST
progression; for instance, anas yet unidentiﬁed tumor-suppressor
gene on the short arm of chromosome 1 has been implicated in
MPNST pathogenesis.14 Finally, it must be pointed out that
MPNSTs have very complex karyotypes,15e26 in which speciﬁc
gains and losses are repeatedly encountered, suggesting that
important driver genes remain undiscovered in these tumors.
A more complete understanding of the various mutations
contributing to plexiform neuroﬁbroma and MPNST patho-
genesis could identify novel molecular targets for therapeutic
intervention. Ideally, this would be accomplished by
sequencing the transcriptome and exome of a large cohort of
human plexiform neuroﬁbromas and MPNSTs, an approach
whose effectiveness has been demonstrated by The Cancer
Genome Atlas (TCGA) in glioblastomas27 and serous ovar-
ian carcinomas.28 However, plexiform neuroﬁbromas and
MPNSTs are much less common than any of the tumor types
thus far examined by TCGA, and it is difﬁcult to obtain large
numbers of these neoplasms for study. Consequently, it likely
will be necessary to complement the sequencing of human
tumors with other approaches, such as identifying the somatic
mutations driving neuroﬁbromaeMPNST progression in an
appropriate mouse model. Indeed, analogous cross-species
comparative oncogenomic studies using genetically engi-
neered mouse cancer models29e32 or murine cancers produced
by insertional mutagenesis with the Sleeping Beauty trans-
poson system33e35 have proven quite useful for the identiﬁ-
cation of driver genes in other types of cancer. Unfortunately, it
is not clear what mouse model can be used to study neuro-
ﬁbromaeMPNST progression. Krox20-Cre;Nf1ﬂox/ mice
develop numerous neuroﬁbromas,36 but these lesions do not
progress to become MPNSTs at an appreciable rate. On the
other hand, mice with cis-linked Nf1 and p53 null alleles do
develop MPNSTs,37,38 but these tumors arise de novo rather
than from a pre-existing neuroﬁbroma. Consequently, neither
of these mouse models recapitulates the process of neuro-
ﬁbromaeMPNST progression seen in human NF1.The American Journal of Pathology - ajp.amjpathol.orgWe have shown that the potent Schwann cell mitogen
neuregulin-1 (NRG1) contributes to the pathogenesis of
human neuroﬁbromas and MPNSTs,39,40 and that transgenic
mice overexpressing this growth factor in Schwann cells (P0-
GGFb3 mice) develop MPNSTs.41 These observations led us
to ask whether P0-GGFb3 mice accurately model human
neuroﬁbromaeMPNST progression and would thus be useful
for identifying the driver gene mutations mediating this
process. To address this question, we ﬁrst determined whether
P0-GGFb3 mice develop neuroﬁbromas and whether there is
pathological evidence that these neuroﬁbromas progress to
become MPNSTs. We then asked whether the molecular
abnormalities driving the pathogenesis of peripheral nerve
sheath tumors in P0-GGFb3 mice parallel those seen in their
human counterparts. Finally, we used high-density array
comparative genomic hybridization (aCGH) to identify addi-
tional previously unknown mutations potentially promoting
the pathogenesis of P0-GGFb3 MPNSTs.
Materials and Methods
Antibodies and Other Reagents
Rabbit polyclonal antibodies recognizing S100b (Z0311)
and glial ﬁbrillary acidic protein (GFAP; Z0334) and a
mouse monoclonal anti-desmin (clone D33) antibody were
purchased from Dako (Carpinteria, CA). A mouse mono-
clonal anti-neuroﬁlament antibody (SMI34) was purchased
from CovanceeSternberger Monoclonals (Lutherville, MD).
Mouse monoclonal antibodies against collagen type IV
(clone PHM-12), smooth muscle actin (SMA; clone 1A4),
and GAPDH (clone 6C5) were purchased from Ventana
Medical Systems (Tucson, AZ), NeoMarkers (Fremont, CA),
and Advanced ImmunoChemical (Long Beach, CA),
respectively. A rabbit polyclonal antibody recognizing
neuron-speciﬁc enolase (NSE; AB591) and a mouse pan-Ras
monoclonal antibody (clone RAS10) were purchased from
Millipore (Billerica, MA). Antibodies against neuroﬁbromin
(sc-67), cyclin D2 (sc-593), p53 (sc-99), p16INK4A (sc-1207),
Mdm2 (sc-965), Mdm4 (sc-28222), p21Cip1/Waf1 (sc-397),
and p27Kip1 (sc-527) were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Mouse monoclonal anti-
bodies recognizing CDK2 (610145), CDK4 (610147), and
cyclin D3 (610279) were purchased from BD Biosciences
(San Jose, CA). Mouse monoclonal antibodies against cyclin
D1 (2926) and Rb phosphorylated on Ser795 (9301) were
purchased from Cell Signaling Technology (Danvers, MA).
Horseradish peroxidase- and Cy3-conjugated secondary
antibodies were purchased from Jackson ImmunoResearch
(West Grove, PA). The pan-ErbB inhibitor PD168393 was
purchased fromMilliporeeEMDChemicals (Billerica, MA).
Animal Care and Necropsies
Mice were cared for in accordance with the NIH Guide
for the Care and Use of Laboratory Animals (8th ed., 2011).647
Kazmi et alAll animal experiments were approved by the Institutional
Animal Care and Use Committee of the University of
Alabama at Birmingham.
P0-GGFb3mice were bred to C57BL/6JSJL/J F1 hybrids
or were backcrossed to purebred C57BL/6J mice (Jackson
Laboratory, Bar Harbor, ME). The resulting offspring were
screened by polymerase chain reaction (PCR) as described
previously.41 Mice were housed in standard cages with water
and food available ad libitum. Moribund mice or mice sus-
pected for other reasons of bearing tumors were anesthetized
with isoﬂurane and sacriﬁced by decapitation. Tumor tissue
was removed fresh, and a portion was used to establish early-
passage cultures. The rest of the tumor was ﬁxed in 4%
paraformaldehyde, except for a small portion that was ﬁxed
with glutaraldehyde. Bodies were then immersion-ﬁxed in
4% paraformaldehyde. After ﬁxation, complete necropsies
were performed, including a detailed examination of the
central and peripheral nervous systems. To examine spinal
cords and nerve roots in situ, vertebral columns together with
adjacent soft tissue and ribs were decalciﬁed by immersion in
0.3 mol/L EDTA/4% paraformaldehyde (pH 8.0) for 48 to
72 hours at 4C. Tissues were dehydrated and parafﬁn-
embedded. Sections (4 to 5 mm thick) were prepared,
stained with H&E, mounted with Permount medium (Fisher
Scientiﬁc, Pittsburgh, PA), and examined with light micros-
copy. All tumor diagnoses were established by a practicing
neuropathologist (S.L.C.) certiﬁed by the American Board of
Pathology in both anatomical pathology and neuropathology.
Tumors were evaluated using World Health Organization
(WHO) diagnostic criteria.42
Immunohistochemical and Histochemical Staining of
Tumor Sections
Schwann cells and axons within peripheral nerve sheath
tumors were identiﬁed by immunostaining parafﬁn sections
(4 to 5 mm thick) according to our previously described
protocol,41 with antibodies recognizing S100b or neuroﬁla-
ments, respectively. Aberrant expression of p53 was examined
by similarly incubating sections with an anti-p53 antibody.
After incubation with horseradish peroxidaseeconjugated
secondary antibody, immunoreactive structures were visual-
ized by diaminobenzidine deposition. To conﬁrm speciﬁcity,
control slides were treated identically, except that primary
antibodies were replaced with nonimmune rabbit or mouse
IgG; no staining was observed in these experiments. After
immunostaining, slides were counterstained with hematox-
ylin, mounted with Permount, and coverslipped for light
microscopic examination.
To examine expression of neuronal and muscle markers
in MPNSTs, double-label immunohistochemistry was per-
formed on tumor sections (4 to 5 mm thick) using a rabbit
polyclonal anti-S100b antibody in combination with mouse
monoclonal antibodies recognizing neuroﬁlaments, desmin,
or SMA. Immunoreactive cells were identiﬁed by then
incubating the sections with Cy3-conjugated anti-rabbit and648ﬂuorescein isothiocyanateeconjugated anti-mouse secondary
antibodies. Sections were counterstained with bisbenzimide
before being mounted in 1:1 PBS:glycerol. To verify the
speciﬁcity of the observed staining, primary antibodies were
omitted from some slides, which were then otherwise iden-
tically processed.
Unna’s methylene blue staining for mast cells was per-
formed as described previously.43
Establishment of Early-Passage Tumor Cultures and
Schwann Cell Cultures
Tumor tissue was sterilely transferred to Hanks’ balanced salt
solution, ﬁnely minced and then incubated in Dulbecco’s
minimal essential medium supplemented with 10% fetal
calf serum (DMEM10), 2 mmol/L forskolin, and 50 nmol/L
NRG1b. (In preliminary experiments, we had found that the
last two components facilitated the initial establishment of
tumor cultures.) Cells were allowed to grow out from
explants until conﬂuent. Cultures were then split and main-
tained for no more than ﬁve to eight passages in DMEM10
without forskolin or NRG1b. Cultures of Schwann cells from
wild-type (WT) and transgenic nerves were established
identically, but were maintained continuously in DMEM10
supplemented with forskolin and NRG1b.
Examination of Tumor Suppressors and Lineage
Markers in MPNST Cultures and Tumor Sections
For S100b and p53 immunostaining, early-passage tumor
cells were plated at low density in chamber slides and
allowed to adhere overnight. Slides were then ﬁxed for 30
minutes at room temperature with 4% paraformaldehyde,
followed by three rinses with PBS (5 minutes per wash).
Fixed cells were incubated for 30 minutes in blocking buffer
(PBS containing 1% bovine serum albumin, 0.2% nonfat dry
milk, and 0.3% Triton X-100) and then incubated overnight
at 4C with anti-S100b antibody diluted 1:200 in blocking
buffer. The next morning, cells were rinsed three times with
PBS and then incubated for 1 hour at room temperature
with Cy3-conjugated donkey anti-rabbit secondary antibody
diluted 1:250 in blocking buffer. After three more rinses in
PBS, slides were mounted using 1:1 PBS:glycerol and were
examined with ﬂuorescence microscopy.
Arrays of tumor cells were constructed as described
previously.40 Sections (4 to 5 mm thick) of the arrays were
prepared, deparafﬁnized, and rehydrated through graded
ethanols to PBS. After 30 minutes in blocking buffer,
rehydrated sections were incubated with primary antibody
or nonimmune IgG overnight at 4C. Dilutions of primary
antibodies were as follows: collagen type IV, 1:50; GFAP,
1:500; NSE, 1:1000; SMA, 1:1000; and desmin, 1:50.
Sections were rinsed three times with PBS and then incu-
bated with horseradish peroxidaseeconjugated secondary
antibodies for 1 hour at room temperature. After three
more PBS washes, immunoreactivity was detected byajp.amjpathol.org - The American Journal of Pathology
Mouse Model of NFeMPNST Progressiondiaminobenzidine deposition. Sections were lightly coun-
terstained with hematoxylin and mounted with Permount for
light microscopic examination.
Primers for ampliﬁcation of tumor cell markers were
designed using Lasergene PrimerSelect software version 3.10
(DNASTAR, Madison, WI). GenBank accession numbers of
the target sequences and the position of each primer are listed
in Table 1. cDNA (2 mL) synthesized from total RNA was
used in PCR reactions (35 cycles of 94C for 1 minute, 55C
for 1 minute, and 72C for 2 minutes).
Immunoblotting
Cells were homogenized in HES buffer (40 mmol/L HEPES,
2 mmol/L EDTA, 500 mmol/L sucrose) supplemented with
protease (P8340; Sigma-Aldrich, St. Louis, MO) and phos-
phatase (P5726; Sigma-Aldrich) inhibitor cocktails at a 1:100
ratio. Protein concentrations were determined using a mod-
iﬁed Lowry method (DC protein assay; Bio-Rad Labora-
tories, Hercules, CA). Equivalent quantities of protein
lysates were resolved on 8% SDS-PAGE gels, immunoblot-
ted according to our previously described protocol,40 and
probed. Immunoreactive species were detected by enhanced
chemiluminescence (Pierce; Thermo Fisher Scientiﬁc,
Rockford, IL). As a loading control, membranes were
reprobed with an anti-GAPDH antibody (1:20,000 dilution).
qPCR
Real-time quantitative PCR (qPCR) was performed using
our previously described protocol44 with an ABI 7500 real-Table 1 PCR Primers Used for Ampliﬁcation of Transcripts
Encoding Differentiation Markers in MPNST Cultures
Tumor marker
GenBank
accession no.
Primer position
Forward Reverse
S100a BC005590 19e39 423e400
S100b NM_009115 28e51 197e175
P0 NM_008623 39e61 490e469
MBP M15060 339e359 767e744
PMP22 NM_008885 1049e1069 1457e1434
p75LNTR BC038365 521e542 935e912
Sox10 BC018551 1845e1864 2257e2237
Pax3 X59358 398e417 811e788
Krox20 X06746 376e399 817e794
GFAP NM_010277 777e798 1210e1187
GAP43 BC028288 362e383 822e799
Neuroﬁlament BC029203 71e92 636e613
Peripherin 1 BC046291 131e151 607e585
Calponin-1 Z19542 546e569 976e953
SM22a U36588 79e97 480e458
aSMA BC064800 655e688 1162e1141
Desmin NM_010043 156e179 556e533
MyoD1 NM_010866 1313e1336 1799e1776
MBP, myelin basic protein; P0, myelin protein zero; p75LNTR, the low
afﬁnity neurotrophin receptor; PMP22, peripheral myelin protein 22; SM22a,
transgelin; aSMA, a-smooth muscle actin.
The American Journal of Pathology - ajp.amjpathol.orgtime PCR system (Life TechnologieseApplied Biosystems,
Foster City, CA). Assays of Cdkn2a and Nf1 transcripts
were performed using FAM-labeled TaqMan MGB probes
(ABI assays Mm00494449_m1 and Mm00812424_m1, re-
spectively). The levels of cDNA encoding 18S ribosomal
RNA were assayed in the same cDNAs using VIC-labeled
TaqMan MGB probes (ABI 4319413E). Each specimen
was assayed in triplicate and the levels of test cDNAs
normalized to that of 18S rRNA cDNA in the same spec-
imen. Assays were analyzed using Applied Biosystems
Sequence Detection Software version 1.4.Ras Activation Assays
Wild-type Schwann cells and early-passage P0-GGFb3
MPNST cultures were lysed in magnesium-containing buffer
[25 mmol/L HEPES (pH 7.5), 150 mmol/L NaCl, 10 mmol/L
MgCl2, 1 mmol/L EDTA, 1% Igepal CA-630, 10% glycerol]
supplemented with phosphatase (78420; 1:100 dilution;
Thermo Scientiﬁc) and protease (P8340; 1:100 dilution;
Sigma-Aldrich) inhibitor cocktails. Lysates were clariﬁed by
centrifugation at 20,000  g for 10 minutes. After determi-
nation of their protein concentrations, lysates were diluted to
0.5 mg/mL protein; 250 mg (500 mL) of protein was then
spiked with 20 mL Ras assay reagent beads (Raf-1 Ras-
binding domain agarose beads; Millipore) and incubated for
30 minutes at 4C with continuous rotation. Beads were
washed three times in magnesium-containing lysis buffer
supplemented with protease and phosphatase inhibitors and
then were collected by centrifugation at 20,000  g for
10 seconds. Beads were boiled for 15 minutes in 40 mL 2
stop buffer [250 mmol/L Tris-HCl (pH 6.8), 5 mmol/L
EDTA, 5mmol/L EGTA, 2%SDS, 10% glycerol, 25mmol/L
dithiothreitol, and 300 mmol/L bromophenol blue]. Material
released from the beads and samples of the clariﬁed lysates
were resolved on 12% SDS-PAGE gels, immunoblotted as
described above, and probed with a pan-Ras antibody.Identiﬁcation of Trp53 Mutations
Nested PCR was used to amplify Trp53 sequences for
sequencing. The cDNA template was synthesized from total
cellular RNA, as described above. The ﬁrst round of PCR was
performedwith primers corresponding tonucleotides 268e287
and 1925e1947 of GenBank accession NM_011640.1. A
portion of the initial PCR product was then further ampliﬁed
with primers corresponding to nucleotides 357e375 and
1780e1802 of GenBank accession NM_011640.1. Both
rounds of PCR ampliﬁcation were performed with an initial
1-minute melt at 94C, followed by 35 cycles of 94C for 30
seconds, 50C for 1 minute, and 72C for 4 minutes, and then
by aﬁnal 7-minute extension at 72C. Final PCRproductswere
gel-puriﬁed and sequenced with primers corresponding to
nucleotides 485e503, 899e922, and 1275e1298 of GenBank
accession NM_011640.1.649
Kazmi et alDNA Synthesis Assays
40,000 MPNST cells were plated per well in DMEM10 and
allowed to attach overnight. The next morning, PD168393 or
vehicle (dimethyl sulfoxide) was added to each well; 12 hours
later, 1 mL of 1 mCi/mL [3H]thymidine was added. After 12
hours of radiolabeling, [3H]thymidine incorporation by
MPNST cells was assayed using our previously described
methodology.40 All experiments were performed in triplicate,
with six replicates per condition performed in each experi-
ment. A one-way analysis of variance, followed by a Tukey’s
post hoc test, was used to analyze the resulting data. AP value
of <0.05 was considered statistically signiﬁcant.
Array Comparative Genomic Hybridization
Genomic DNA was isolated from early-passage P0-GGFb3
MPNST cells and cultured WT (nontransgenic) mouse
Schwann cells using a QIAamp DNA mini kit (Qiagen,
Valencia, CA) according to the manufacturer’s recommen-
dations. Test (MPNST) and reference (Schwann cell) ge-
nomic DNA was labeled with Cy5-dUTP and Cy3-dUTP,
respectively, using a genomic DNA enzymatic labeling kit
(Agilent Technologies, Santa Clara, CA) according to the
manufacturer’s recommendations. Whole-genome aCGH
was performed using mouse 4x44k oligonucleotide arrays
(Agilent Technologies), which have an overall median probe
spacing of approximately 22 kb, and median probe spacing in
RefSeq genes of approximately 13 kb. Slide hybridization,
washing, and scanning were performed according to the
manufacturer’s protocol. The arrays were scanned using
a GenePix 4000B scanner (Molecular Devices, Sunnyvale,
CA). The resulting data were analyzed using Feature
Extraction version 9.5 and DNA Analytics version 4.0 soft-
ware (Agilent Technologies). The analysis parameters used
for the detection of genomic copy number variations (CNVs)
included linear dye normalization, ADM-2 aberration detec-
tion algorithm, and aberration ﬁlter of four sequential probes
with a log2 ratio cutoff of 0.25. All genomic breakpoints were
mapped using mouse genome build NCBI37/mm9. The data
sets resulting from these aCGH experiments have been
deposited in the NCBI Gene Expression Omnibus under
accession number GSE40212. The called CNVs identiﬁed in
these experiments have also been deposited in the NCBI
Database of Genomic Structural Variation (dbVar) under
study ID number nstd74.
Results
P0-GGFb3 Mice Develop Numerous Neuroﬁbromas
Throughout Their Peripheral Nervous System That
Progress to Become MPNSTs at a High Frequency
If MPNSTs arising in P0-GGFb3 mice develop via pro-
gression from pre-existing neuroﬁbromas, neuroﬁbromas
should be evident in these animals. Because only a subset of650these neuroﬁbromas would be expected to accumulate the
additional mutations required for progression, neuroﬁbromas
should also be more common than MPNSTs in P0-GGFb3
mice. To test these postulates, we established a cohort of 44
mice (21 female and 23 male) carrying the P0-GGFb3 trans-
gene on an outbred C57BL/6JSJL/J background and fol-
lowed them until their death (mean age at death, 261.5 days;
median, 220.5 days; range, 74 to 533 days). Complete
necropsies were performed, including histological examina-
tion of longitudinal sections of the decalciﬁed vertebral
column and adjacent soft tissue. The peripheral nerve sheath
tumors that were identiﬁed were evaluated using World
Health Organization diagnostic criteria for neuroﬁbromas and
MPNSTs.42 In the vast majority of these animals (41/44mice;
91%), virtually every dorsal spinal nerve root was markedly
enlarged by intraneural tumor growth (Figure 1A). Histo-
logical examination of these neoplasms showed them to be
moderately cellular lesions that did not demonstrate the
hypercellularity, increased nuclear size, hyperchromasia, or
increased mitotic activity seen in low-grade MPNSTs. The
tumors were predominantly composed of elongated cells with
spindled nuclei (Figure 1B) that diffusely inﬁltrated nerve
roots and dorsal root ganglia, as demonstrated by the presence
of entrapped neurons and axons (Figure 1, B and E). Prom-
inent immunoreactivity for the Schwann cell marker S100b
was evident in a major population of intratumoral cells that
were intimately intermingled with S100b-negative cells
(Figure 1C). These intraneural tumors additionally contained
large numbers of mast cells, which were demonstrable by
prominent metachromasia under methylene blue staining
(Figure 1D). Similar neoplasmswere present in the trigeminal
ganglia and sympathetic nervous system (superior cervical,
celiac, and superior mesenteric ganglia and associated nerves)
of these P0-GGFb3 mice. Considered in aggregate, the
histopathological features of the low-grade neoplasms oc-
curring in the dorsal spinal nerve roots, trigeminal ganglia,
and sympathetic nervous system of P0-GGFb3 mice are
identical to those seen in human neuroﬁbromas.
While evaluating the tumors described above,we found that
5 of the 44 mice had neuroﬁbromas that contained small foci
with a higher-grade appearance (Figure 1F). These foci were
composed of closely packed, markedly atypical cells with
angulated, hyperchromatic nuclei andmultiplemitotic ﬁgures.
A comparison of these foci to the MPNSTs that developed in
P0-GGFb3mice (see below) demonstrated a striking similarity
between the atypical foci andmany of the higher-grade lesions
found in these animals (eg, compare the focus illustrated in
Figure 1F to the high-grade tumors in Figure 2, B andD). This
observation suggests that the neuroﬁbromas developing in P0-
GGFb3 mice are the precursors that ultimately give rise to
MPNSTs in these animals.
MPNSTs were identiﬁed in 31 (71%) of the necropsied
P0-GGFb3 mice. Grossly, these large nerve-associated
tumors had a ﬂeshy appearance, with areas of hemorrhage
and necrosis often evident. Microscopic examination showed
them to be markedly hypercellular lesions with brisk mitoticajp.amjpathol.org - The American Journal of Pathology
Figure 2 Representative images of MPNSTs arising in P0-GGFb3 mice,
demonstrating the histological variability encountered in these neoplasms.
A and B: Histology of tumors that arose independently in the left (A) and
right (B) trigeminal nerves of mouse B76. Note the extreme spindled
morphology of the tumor cells in A, which contrasts markedly with the
densely packed, poorly differentiated cells composing the tumor seen in B.
C: MPNST with an epithelioid morphology that arose in the sciatic nerve of
mouse A202. D: A trigeminal MPNST from mouse A387 invading the
undersurface of the brain. The overlying brain parenchyma (asterisk) is
being invaded by this tumor. Scale bars: 50 mm (AeC); 200 mm (D).
Figure 1 P0-GGFb3 mice develop multiple neuroﬁbromas that may
undergo malignant transformation. A: Low-power image of a representative
neuroﬁbroma developing on a dorsal spinal nerve root in a P0-GGFb3mouse. B:
Higher-power view of the same tumor section, showing entrapped ganglionic
neurons (arrows).C: In a sectionof the same tumor, immunostaining for S100b
reveals coexistence of S100b-positive and -negative elements within this
neoplasm. D: In a section of the same tumor, Unna’s methylene blue stain
reveals numerous mast cells, evident by their prominent metachromasia (cells
with dark purple granules) (arrows).E: In another tumor, immunostainingwith
the anti-neuroﬁlament antibody SMI34 reveals axons (arrows) entrapped by
inﬁltrating tumor cells. F: Microscopic focus of apparent malignant trans-
formation, a markedly hypercellular region (left half of the ﬁeld), arising in
a spinal nerve root neuroﬁbroma. Scale bars: 500 mm (A); 50 mm (BeF).
Mouse Model of NFeMPNST Progressionactivity that were histologically similar to human MPNSTs
(Figure 2). Most of these MPNSTs were composed of closely
packed, hyperchromatic cells with eosinophilic cytoplasm
(Figure 2, B andD) and resembled the high-grade tumors seen
in our initial studies of these animals.41 With this larger
sampling of tumors, however, it became apparent that the
MPNSTs developing in P0-GGFb3 mice, like human
MPNSTs,42 were morphologically diverse, with neoplasms
that arose independently in the same animal sometimes
differing markedly in appearance [eg, compare the extreme
spindled morphology of the tumor cells in the neoplasm
which arose in the left trigeminal nerve of mouse B76
(Figure 2A) to that of the densely packed, poorly differenti-
ated cells evident in a tumor which arose in the right
trigeminal nerve of this samemouse (Figure 2B)]. Occasional
MPNSTs even had an epithelioid appearance (Figure 2C).
Nonetheless, all of these tumors expressed S100b, as ex-
pected for MPNSTs. In contrast to the neuroﬁbromas, which
were conﬁned to their nerve of origin, the MPNSTs were
locally aggressive, commonly invading adjacent organs
(Figure 2D), soft tissue, bone, and skeletal muscle.The American Journal of Pathology - ajp.amjpathol.orgIn contrast to neuroﬁbromas, which typically occurred in
large numbers in tumor-bearing P0-GGFb3 mice, MPNSTs
were much less common. Of the 31 mice, 23 (74%) with these
higher grade neoplasms had only a single MPNST, with
6 animals (19%) having two MPNSTs and 2 animals (6%)
having three or ﬁve MPNSTs. In 24 (77%) of the 31
P0-GGFb3 mice with MPNSTs, the neoplasms arose in
trigeminal nerves. Spinal nerve roots and sciatic nerves were
also common sites of MPNST occurrence [10/31 animals
(32%)], with the remainder developing in the region of the
superior cervical ganglion [2/31 mice (6.5%)]; the summed
percentages exceed 100% because some animals developed
multiple neoplasms. MPNSTs occurred with similar frequen-
cies in male [16/23 (70%)] and female [15/21 (71%)] mice.
To further conﬁrm these ﬁndings, we performed complete
necropsies on a second cohort of 18 P0-GGFb3 mice that
had been backcrossed onto a C57BL/6J background for ﬁve
to eight generations and followed until their death. The
incidence and distribution of neuroﬁbromas and MPNSTs
in these animals was highly similar to that seen in mice
carrying the P0-GGFb3 transgene on a C57BL/6JSJL/J
background, except that the frequency with which they
developed MPNSTs was higher (15/18 mice; 83%).
P0-GGFb3 MPNSTs, Like HumanMPNSTs, Demonstrate Ras
Hyperactivation, Abnormalities in Cell-Cycle Regulatory
Pathways, and a Continuing Dependence on Aberrant
Growth-Factor Signaling
In human NF1, loss of the NF1 gene promotes the initial
pathogenesis of neuroﬁbromas, with the subsequent651
Kazmi et aldevelopment of MPNSTs being driven, in part, by the accu-
mulation of additional abnormalities in pathways regulating
cell-cycle progression. The stepwise progression of tumori-
genesis in P0-GGFb3 mice suggested that this process simi-
larly involves the sequential mutation of multiple driver
genes. We therefore examined P0-GGFb3 MPNSTs to
determine whether they exhibit Nf1 and cell-cycle regulatory
abnormalities analogous to those commonly found in human
MPNSTs. We focused on MPNSTs in these experiments for
two reasons. First, MPNSTs represent the culmination of the
neoplastic process in P0-GGFb3 mice and thus are the lesions
most likely to demonstrate the full spectrum of driver muta-
tions. Second, beyond a loss of NF1, mutations of tumor
suppressors or other driver gene abnormalities have not yet
been identiﬁed in human neuroﬁbromas.
Because only a limited amount of MPNST tissue can be
obtained from an individual P0-GGFb3 mouse, we developed
a methodology for establishing early-passage (no more than
ﬁve to eight passages) cultures from P0-GGFb3 MPNSTs for
use in these experiments. In light of the histological diversity
we had observed in P0-GGFb3MPNSTs, we ﬁrst validated the
identity of these cultures using an extensive panel of markers
previously examined in human MPNSTs and/or in MPNSTs
arising in other genetically engineered mouse models. Initial
immunostaining veriﬁed that early-passage cultures estab-
lished from 18 independently arising P0-GGFb3 MPNSTs
retained their immunoreactivity for S100b (Figure 3, A and B).
Encouragedby thisﬁnding,we constructed arrays of these cells
and probed sections of the arrays for additional Schwann cell
markers (collagen type IV and GFAP) and markers of other
lineages (NSE, SMA, and desmin). All of the cultures were
collagen type IV immunoreactive (data not shown), and 12 of
the 18 cultures expressed GFAP (Figure 3C). In contrast, NSE
immunoreactivity was not found in any of these cells. Notably,
however, 17 of the 18 cultures were SMA immunoreactive
(Figure 3D), with 5 cultures (eg, A202 cells) labeling also for
desmin. We therefore expanded our analyses to include an
extensive panel of markers (Figure 3E) that has been previ-
ously examined in another genetically engineered mouse
MPNST model (cis-Nf1þ/;p53 mice).37
Using RT-PCR, we found that the overwhelming majority
of our early-passage cultures expressed transcripts encoding
a series of classic Schwann cell markers [S100b, myelin
protein zero (P0), peripheral myelin protein-22 (PMP22), the
low-afﬁnity neurotrophin receptor (p75LNTR), and the tran-
scription factor genes Sox10, Pax3, and Egr2 (also known as
Krox20)], with some other Schwann cell markers [myelin
basic protein (MBP), GFAP, and GAP-43] evident in a subset
of these cultures. Transcripts for several muscle markers
(calponin, SM22a/transgelin, and a-SMA) were almost
uniformly present in the P0-GGFb3 MPNST cells, whereas
the expression of neuronal markers was more restricted (light
neuroﬁlaments were present in 5/18 cultures, and peripherin
was present in 3/18 cultures). PCR products of an identical
size were detected for all these markers in control tissues and
were absent when PCR reactions were performed using652cDNA synthesis reactions in the absence of reverse tran-
scriptase or with water blanks (Supplemental Figure S1A).
Thus, early-passage cultures derived from P0-GGFb3
MPNSTs show clear evidence of Schwannian differentia-
tion. However, these cells can also express muscle markers
and, less frequently, neuronal markers, suggesting that they,
like MPNSTs arising in humans and in cis-Nf1;p53 mice,
are capable of expressing markers associated with other
lineages. To verify that the expression of neuronal and
muscle markers in our cultures was not a culture artifact, we
performed double-label immunohistochemistry for S100b
and neuroﬁlaments, desmin, or SMA on sections of the
MPNSTs that were used to derive cultures positive for
these markers. S100b immunoreactive cells within these
neoplasms were also labeled by antibodies recognizing
neuroﬁlaments, desmin, and SMA (Figure 3, FeU), indi-
cating that our in vitro observations accurately reﬂected the
phenotype of the parent tumor.
Having thus validated the phenotype of our early-passage
cultures, we next examined neuroﬁbromin expression in these
cells. In these and subsequent analyses, we compared
expression in MPNST cells to that in non-neoplastic trans-
genic Schwann cells, because this allowed us to identify
changes in tumor suppressor and oncogene expression that
are associated with tumor pathogenesis rather than with
transgene expression. Lysates of MPNST cultures and non-
neoplastic Schwann cells derived from the nerve type
(trigeminal or sciatic) in which the tumors arose were im-
munoblotted and probed with an antibody that recognizes
both of the major neuroﬁbromin splice variants (220 and 250
kDa). Neuroﬁbromin expression in P0-GGFb3 MPNST cells
was typically equal to or higher than that seen in non-
neoplastic Schwann cells (Figure 4A). qPCR assays simi-
larly revealed little evidence of a reduction in Nf1 mRNA
levels (Supplemental Figure S1B).
We next asked whether P0-GGFb3 MPNST cells show
evidence of the Ras hyperactivation characteristic of human
NF1/ MPNST cells.45,46 To compare the relative levels of
activated Ras in non-neoplastic Schwann cells and in three
representative P0-GGFb3 MPNST cultures, a GST fusion
protein containing the Raf1 Ras binding domain was used to
pull down activated Ras proteins from lysates of these cells.
Proteins captured with the Raf1 Ras binding domain were
immunoblotted and probed with a pan-Ras antibody that
recognizes all three members (H-Ras, N-Ras, and K-Ras) of
the classic Ras subfamily. Although activated Ras was
undetectable in non-neoplastic Schwann cells, it was easily
identiﬁed in P0-GGFb3 MPNST cells (Figure 4B). There-
fore, although neuroﬁbromin expression is maintained in
P0-GGFb3 MPNSTs, these tumors, like neuroﬁbromin-null
human MPNSTs,46,47 exhibit Ras hyperactivation.
A number of laboratories have reported mutation or dys-
regulation of p53 in human MPNSTs.11e13,48,49 To deter-
mine whether p53 abnormalities are similarly present in
P0-GGFb3 MPNSTs, we ﬁrst immunostained tumors and
early-passage cultures derived from these tumors for p53.ajp.amjpathol.org - The American Journal of Pathology
Figure 3 Early-passage P0-GGFb3 MPNST cells
consistently express multiple Schwann cell markers
and variably express neural and muscle markers. A
and B: Early-passage cultures of tumors arising on
mixed C57BL/6SJL (A390 cells) (A) or inbred
C57BL/6 (B91 cells) (B) backgrounds uniformly
express the Schwann cell marker S100b (Cy3
immunoreactivity; red-orange staining). These
cells have been counterstained with the nuclear
stain bisbenzimide (blue). C and D: Immuno-
staining of array sections reveals the expression of
other markers, such as GFAP (C) and SMA (D), that
was observed in some lines. Sections have been
lightly counterstained with hematoxylin. E: RT-PCR
for Schwann cell (S100b, P0, MBP, PMP22, p75
LNTR,
Sox10, Pax3, Krox20, GFAP, GAP43), neural (neu-
roﬁlament, peripherin), and muscle (calponin,
SM22a, a-SMA, desmin, MyoD1) markers in early-
passage cultures established from 18 indepen-
dently arising P0-GGFb3 MPNSTs. F-U: Double-label
immunohistochemistry for S100b and neuroﬁla-
ments (FeI), desmin (JeM), or SMA (NeQ) per-
formed on the parent tumors (A391 and A387)
used as the source of MPNST cultures that aber-
rantly expressed neuronal and/or muscle markers.
For controls (ReU), immunostains were performed
with secondary antibodies alone, in the absence of
primary antibodies. Sections were counterstained
with bisbenzimide (Bis).
Mouse Model of NFeMPNST ProgressionAlthough p53 immunoreactivity (indicative of p53 over-
expression or increased p53 half-life) was not uniformly
present, it was evident in six of the eighteen neoplasms and
early-passage cultures derived from these neoplasms
(Figure 5, AeF). This immunoreactivity was present
predominantly in the nuclei of the tumor cells, with light
staining at times evident also in the cytoplasm. To addition-
ally determine whether the presence of p53 immunoreactivity
in these MPNSTs reﬂects tumor progression, we also
immunostained a series of 13 P0-GGFb3 neuroﬁbromas with
an anti-p53 antibody. In contrast to the MPNSTs, none of the
neuroﬁbromas exhibited p53 immunoreactivity.
To compare the expression of p53 in P0-GGFb3 MPNSTs
to that in non-neoplastic Schwann cells, lysates of Schwann
cells derived from the sciatic and trigeminal nerves of
P0-GGFb3 mice and early-passage MPNST cultures were
immunoblotted and probed for p53. In both non-neoplastic
transgenic Schwann cells (Figure 5G) and WT Schwann
cells (data not shown), p53 was undetectable. In contrast, the
MPNSTs with prominent nuclear p53 immunoreactivityThe American Journal of Pathology - ajp.amjpathol.org(A202, A18, A387, A390, B76, and B97) all exhibited
increased p53 expression in immunoblot analyses. The p53
immunoreactive species detected in these tumors had a mass
of 53 kDa, with the exception of tumor A390; in this
neoplasm, the p53 antibody recognized a species with a lower
molecular weight, suggesting the occurrence of a truncating
mutation or a deletion.
To identify potential p53 mutations in these tumors, nested
PCR was used to amplify Trp53 sequences from the 18 early-
passage P0-GGFb3 MPNST cultures, and the resulting
products were sequenced in their entirety. In keeping with the
size shift seen in immunoblots, the Trp53mRNAexpressed in
tumor A390 had a frameshift mutation in codon 314, which is
within the p53 tetramerization domain. We also found that
tumor A202 expressed a transcript with a small in-frame
deletion (codons 164 to 172) within the region encoding the
p53 DNA binding domain. In tumor B76, a point mutation
(c.R207C) was identiﬁed. The online tool Mutation Assessor,
which assesses the likely effect of a mutation based on the-
nature of the change and whether it occurs in a conserved653
Figure 4 Although neuroﬁbromin expression is
typically maintained in P0-GGFb3 MPNSTs, Ras is
hyperactivated in these neoplasms, compared with
WT Schwann cells. A: Immunoblotted lysates of WT
and non-neoplastic transgenic Schwann cells and 18
early-passage P0-GGFb3 MPNST cultures probed for
neuroﬁbromin (1:500 antibody dilution). The 250-
kDa form of neuroﬁbromin is present in Schwann
cells and the MPNST cells, with some MPNST cultures
also exhibiting the 220-kDa splice variant of this
protein.B: The Raf-1 Ras-binding domain (RBD) was
used to pull down activated Ras protein in WT
Schwann cells and three early-passage P0-GGFb3
MPNST cultures. An immunoblot of the captured
activated Ras proteins was then probed with a pan-
Ras antibody that detects H-Ras, K-Ras, and N-Ras
(upper panel). Themiddle and lower panels show
immunoblots of the clariﬁed lysate before Ras pull-
down probedwith the pan-Ras antibody and an anti-
GAPDH antibody, respectively.
Kazmi et alregion, predicts that the c.R207C mutation has a high prob-
ability of affecting p53 function (http://mutationassessor.org,
release 1, last accessed July 2012). Although tumor B97
showed no evidence of mutations within Trp53 coding
sequences, a 95-bp duplication was evident within the 30
untranslated region of this mRNA. No Trp53 mutations were
identiﬁed in the p53-overexpressing A18 and A387 tumors,
nor in any of the tumors lacking p53 overexpression.654Considered collectively, these ﬁndings indicate that 33%
(6/18) of the P0-GGFb3 MPNSTs we examined have
abnormal expression or mutation of p53.
Dysregulation of the p19ARFeMdmep53 pathway can also
result from overexpression of Mdm2 or Mdm4, two proteins
that promote the ubiquitination of p53 and its degradation by
proteasomes. To determine whether Mdm2 or Mdm4
overexpression occurs in P0-GGFb3 MPNSTs, lysates ofFigure 5 Abnormalities in the p19ARFeMdmep53
signaling pathway occur in early-passage P0-GGFb3
MPNST cultures. AeF: Immunocytochemistry reveals
intranuclear accumulation of p53 in two representative
p53-overexpressing P0-GGFb3 MPNST early-passage
cultures. p53 immunoreactivity is indicated by red-
orange staining (A and D); bisbenzimide was used as
a nuclear counterstain (blue) (B and E). Merged images of
p53 immunoreactivity and bisbenzimide staining (C and
F) demonstrate that p53 in these tumor cells accumulates
within the nuclei. G: Immunoblotted lysates of non-
neoplastic transgenic Schwann cells and early-passage
cultures derived from 18 independently arising P0-
GGFb3 MPNSTs probed for p53 (1:1000 dilution). Blots
were reprobed with GAPDH to verify equivalent loading.
H: Immunoblotted lysates of non-neoplastic transgenic
Schwann cells and early-passage cultures derived from 18
independently arising P0-GGFb3MPNSTs probed forMdm2
or Mdm4 (each at 1:500 dilution). Blots were reprobed
with GAPDH to verify equivalent loading. Original
magniﬁcation, 40 (AeF).
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Mouse Model of NFeMPNST Progressionnon-neoplastic Schwann cells from the sciatic and trigem-
inal nerves of P0-GGFb3 mice and early-passage tumor
cultures were lysed, immunoblotted, and probed for these
two molecules. Mdm2 and Mdm4 were undetectable in
non-neoplastic transgenic Schwann cells (Figure 5H). In
contrast, three of theMPNST early-passage cultures (A292,
A387, and A390) exhibited prominent Mdm2 overex-
pression; two of the positive specimens (A387 and A390)
also had p53 overexpression. Mdm4 overexpression was
evident in one tumor (B96). These results suggest that the
p19ARFeMdmep53 pathway is dysregulated by Mdm2 or
Mdm4 overexpression in some P0-GGFb3 MPNSTs.
In human MPNSTs, the p16INK4Aecyclin D/CDK4eRb
signaling pathway, which controls S-phase entry, is often
dysregulated.48,50e57 This disruption can occur via multiple
mechanisms, including CDK4 overexpression, a loss of Rb
expression or inappropriate Rb phosphorylation occurring as
a result of p16INK4A mutation, CDK4 overexpression, or
overexpression of D-cyclins. To determine whetherThe American Journal of Pathology - ajp.amjpathol.orgabnormalities of this cell-cycle regulatory pathway occur in
P0-GGFb3 MPNSTs, lysates of non-neoplastic P0-GGFb3
Schwann cell and early-passage P0-GGFb3 MPNST cultures
were immunoblotted and probed for proteins within this
pathway. Cyclins D1, D2, and D3 were all detectable in at
least someMPNSTs (Figure 6A), and often were expressed at
levels higher than those evident in non-neoplastic Schwann
cells. Overexpression of CDK4 was also seen in some tumors
(eg, A202, A382, B76, and B91). Because our preliminary
experiments indicated that detection of p16INK4A protein was
problematic even in non-neoplastic Schwann cells, we
instead used qPCR to quantify levels of the Cdkn2a mRNA
encoding this protein in our cultures (Figure 6B). Compared
with non-neoplastic transgenic Schwann cells, Cdkn2a
mRNA expression was greatly decreased (10-fold to more
than 10,000-fold) in 10 tumors, and was completely unde-
tectable in three other tumors (A387, A394, and B91). Rb
protein and mRNA levels were unchanged in these P0-
GGFb3 MPNSTs (data not shown). However, in keepingFigure 6 Abnormalities in cell-cycle regulatory
proteins are common in early-passage cultures of P0-
GGFb3 MPNST cells, but these cells are persistently
dependent on aberrant growth factor signaling. A:
Immunoblotted lysates of non-neoplastic transgenic
Schwann cells and early-passage cultures of P0-
GGFb3 MPNST cells probed for cyclin D1 (1:300
dilution), cyclin D2 (1:500 dilution), cyclin D3 (1:700
dilution), CDK4 (1:500 dilution), CDK2 (1:400 dilu-
tion), p27Kip1 (1:600 dilution), p21Cip1 (1:500 dilu-
tion), or Rb phosphorylated on Ser795 (1:700
dilution). Blots were reprobed with GAPDH to verify
equivalent loading. B: qPCR analyses of Cdkn2a
expression in non-neoplastic transgenic Schwann
cells and early-passage cultures of P0-GGFb3 MPNST
cells. Transcript levels were normalized to levels
detected in non-neoplastic transgenic Schwann cells.
C: The ErbB inhibitor PD168393 inhibits DNA
synthesis in early-passage cultures of P0-GGFb3
MPNST cells in a concentration-dependent fashion.
[3H]thymidine incorporation relative to vehicle is
shown for four early-passage cultures (A292, A231Tr,
A231Sc, and A390) derived from MPNSTs arising in
P0-GGFb3 mice. Data are expressed as means SEM.
*P < 0.05 versus control. n.d., not detectable.
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Table 2 Whole Chromosome and Large Region Gains and Losses
in P0-GGFb3 MPNSTs
Chromosome and gain or loss Tumor cultures
Chromosome 1
Whole chromosome gain B86, B91, B96
Chromosome 3
Whole chromosome gain A18, B76
Chromosome 4
Whole chromosome loss A202
Chromosome 6
Whole chromosome gain A18, B76, B86, B91
Chromosome 7
Whole chromosome gain A18, A292
Chromosome 8
Whole chromosome loss A202
Whole chromosome gain B76
Chromosome 9
Whole chromosome loss A202, A390
Chromosome 10
Whole chromosome gain A382
Loss (3051,721e50,790,081) B76
Chromosome 11
Whole chromosome gain A18, A202, A231Tr, A292,
A382, A390, A394, B76,
B86, B91, B96
Chromosome 12
Whole chromosome gain A231Tr, A202
Loss (86,353,623e120,684,848) A382
Chromosome 13
Kazmi et alwith the fact that D-cyclin overexpression, CDK4 over-
expression and/or p16INK4A loss was present in most of the
tumors, levels of Rb phosphorylated on Ser795 (amodiﬁcation
that promotes cell-cycle progression) were increased in the
majority of these MPNSTs (Figure 6A). We conclude that
dysregulation of the p16INK4A-cyclin D/CDK4eRb pathway
is quite common in P0-GGFb3 MPNSTs, much as in their
human counterparts.
Expression of p21Cip1/Waf1 and p27Kip1, a pair of proteins
that impede G1eS progression via their effects on CDK2,
cyclin E, and Rb, is also lost in some humanMPNSTs.55,58,59
We therefore examined our early-passage P0-GGFb3
MPNST cultures to determine whether they had similarly lost
expression of these cell-cycle inhibitors. Expression of
p27Kip1, but not p21Cip1/Waf1, was commonly decreased,
compared with non-neoplastic Schwann cells (Figure 6A).
Interestingly, CDK2, a key target of p27Kip1 and p21Cip1/Waf1,
was also overexpressed in 16/18 tumors (Figure 6A). These
ﬁndings thus provide further evidence that cell-cycle pro-
gression is dysregulated in P0-GGFb3 MPNSTs.
Abnormalities affecting cell-cycle regulatory proteins can
render a tumor growth-factor independent. Consequently, we
next asked whether P0-GGFb3 MPNSTs are persistently
dependent on NRG1/ErbB signaling. To address this ques-
tion, early-passage cultures derived from four indepen-
dently arising P0-GGFb3 MPNSTs were challenged with
10 nmol/L to 1 mmol/L concentrations of the pan-ErbB
inhibitor PD168393; [3H]thymidine incorporation was then
assessed in these cultures. Although some variability in their
sensitivity to PD168393 was noted (eg, A231Sc cells were
less sensitive), all four of the early-passage cultures exhibited
a decrease in DNA synthesis, which occurred in a concen-
tration-dependent manner (Figure 6C). We conclude that,
despite the occurrence of cell-cycle protein abnormalities in
P0-GGFb3 MPNSTs, these tumors remain persistently de-
pendent on growth factor signaling.Whole chromosome loss A202
Chromosome 14
Loss (12,738,652e125,076,290) A18
Loss (8760,452e125,076,290) A202
Gain (8794,768e125,076,290) B76
Chromosome 15
Whole chromosome gain A18, A231Tr, B76, B91
Chromosome 16
Whole chromosome loss A202, A390
Chromosome 17
Whole chromosome gain A18, A292, A394,
B76, B91
Chromosome 18
Whole chromosome loss A390
Chromosome 19
Whole chromosome loss A202, A390
Whole chromosome gain A382, B86, B96
Gain (10,320,214e61,216,212) B91
Chromosome X
Whole chromosome gain A18, A202, A390,
A394, B91Whole-Genome aCGH of P0-GGFb3 MPNSTs Identiﬁes
Multiple Areas of Chromosomal CNVs Affecting Genes
Implicated in Neoplasia
These ﬁndings indicated that MPNSTs arising in P0-GGFb3
mice exhibit abnormalities in cell-cycle regulatory signaling
cascades that parallel those in human MPNSTs. This in turn
suggested that an examination of other genomic abnormal-
ities evident in P0-GGFb3 MPNSTs might identify addi-
tional, previously unknown driver genes involved in the
pathogenesis of these sarcomas. To identify somatic CNVs
potentially affecting key driver genes, genomic DNAs iso-
lated from 11 P0-GGFb3 MPNST early-passage cultures
and cultured non-neoplastic nontransgenic Schwann cells
were labeled with Cy5-dUTP and Cy3-dUTP, respectively.
Equal amounts of MPNST and Schwann cell DNA were
then hybridized to high-density aCGH microarrays, and the
relative ratios of the signals from each genomic DNA were656compared, to identify regions of unbalanced chromosomal
gain or loss.
CNVs affecting whole chromosomes or entire chromo-
some arms were common in P0-GGFb3 MPNSTs, occurring
an average of 5.3 times (median, 4; range, 3 to 10) in each
tumor genome (Table 2). Unbalanced gains predominated,
with an average of four per genome (median, 3; range,
2 to 7), with whole chromosome gains evident in everyajp.amjpathol.org - The American Journal of Pathology
Mouse Model of NFeMPNST ProgressionMPNST examined. However, the distribution of these
unbalanced gains was nonrandom. Strikingly, all 11 of the
early-passage MPNST cultures exhibited gains of chromo-
some 11. Gains of chromosome 17 and the X chromosome
were also common, occurring in 5 of the 11 cultures. In
addition, gain of chromosomes 1, 3, 6, 7, 12, 15, 16, and 19
was observed in multiple tumors, albeit at a lower rate. In
contrast, unbalanced losses of whole chromosomes or chro-
mosome arms were less common, with an average of 2.8 per
genome in affected tumors (median, 1; range, 1 to 7) and
occurring in only ﬁve P0-GGFb3 MPNSTs. These losses
were also nonrandom, with unbalanced losses of chromo-
somes 9, 14, 16, and 19 identiﬁed in multiple tumors.
The observation that chromosome 11 was uniformly
ampliﬁed in the P0-GGFb3 MPNSTs we examined was
curious, because this mouse chromosome carries the Nf1
and Trp53 genes, whose equivalents are commonly lost in
human MPNSTs. This led us to examine chromosome 11 in
more detail, to determine whether smaller areas of unbal-
anced loss are present, affecting either the Nf1 or the Trp53
gene. Consistent with our observation that neuroﬁbromin
expression is maintained in these tumors, we found no
evidence of small losses affecting the Nf1 locus in any of
the 11 tumors studied with aCGH. However, one tumor
(A18) exhibited a relative loss of a 1.21-Mb segment
(chr11:68,846,711e70,058,031) containing the Trp53 gene
(Figure 7). This ﬁnding, combined with our mutational
analyses of Trp53, suggests that the p19ARFeMdmep53
cascade in tumor A18 was impaired by both mutation of
a Trp53 allele and an overall reduction in Trp53 copy
number. Unbalanced losses affecting the Trp53 gene were
not evident in any of the other 10 MPNSTs we studied.
During the course of our examination of chromosome 11,
we also noted two other small areas of relative loss that were
present in multiple P0-GGFb3 MPNSTs. Five tumors (A202,Figure 7 aCGH analysis of the 2.47-Mb region in chromosome 11 encoding th
indicates the location of the genes present within the region illustrated in the ac
non-neoplastic Schwann cell (green) DNAs in the MPNST. The height of the colore
1.21-Mb region in which there is a relative copy number loss in the tumor.
The American Journal of Pathology - ajp.amjpathol.orgA292, A382, B76, and B86) exhibited a relative copy number
loss that overlapped in a 225-kb region on chromosome 11
(chr11: 120,322,621e120,548,454; Figure 8); this region
includes 24 known genes. To identify candidate driver genes
within this interval, we compared these genes to the online
comprehensive lists of driver genes available from the Atlas
of Genetics and Cytogenetics in Oncology and Hema-
tology,60 CANgenes,61 CIS,62 and the Sanger Cancer Gene
Census.63 We found that two genes within this interval [Mafg
(v-maf musculoaponeurotic ﬁbrosarcoma oncogene family,
protein G [avian] and Aspscr1 (alveolar soft part sarcoma
chromosome region, candidate 1 [human])] have been
previously identiﬁed as genes that are affected in one or more
cancer types. In addition to the region noted above, a 44-kb
region (chr11: 97,526,341e97,570,620) containing four
genes (Mllt6, Cisd3, Pcgf2, and Psmb3) also exhibited
a relative reduction in copy number in tumors A202 and B76
(Figure 9). Examination of the databases noted above showed
that one of these genes within this interval, Mllt6, has been
previously implicated in the pathogenesis of acute myelocytic
leukemias.64 Considered together, these observations suggest
that multiple regions of relative copy number loss on chro-
mosome 11 affect genes potentially relevant to MPNST
pathogenesis.
Unlike human cancers, in mouse cancer the genomes tend
to have whole chromosome gains or losses with only
a limited number of small CNVs. However, those small
regions of unbalanced gain or loss that do occur in murine
cancers develop under strong selective pressure, which
implies that they contain important driver genes.65 Conse-
quently, we next focused our attention on the small CNVs
occurring in P0-GGFb3 MPNSTs. In our 11 early-passage
MPNST cultures, 44 focal regions of unbalanced chromo-
somal gain and loss were evident. These small CNVs, which
included 26 unbalanced gains and 18 unbalanced losses,e Trp53 tumor suppressor gene in P0-GGFb3 MPNST A18. The genomic map
companying panel, which indicates the relative signals in tumor (red) and
d bar indicates the relative difference in these two signals. Note the central
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Figure 8 aCGH analyses of a 1.1-Mb region in chromosome 11 that surrounds a region of relative copy number loss present in ﬁve P0-GGFb3 MPNSTs (A202,
A292, A382, B76, and B86). The genomic map indicates the location of the genes present within the region illustrated in the accompanying panels, which
indicate the relative signals in tumor (red) and non-neoplastic Schwann cell (green) DNAs in the MPNSTs. The height of the colored bar indicates the relative
difference in these two signals. Note the variably sized central regions in which there is a relative copy number loss in these ﬁve MPNSTs.
Kazmi et alwere spread across 15 chromosomes (Figure 10). Several
of the small CNVs were evident in multiple P0-GGFb3
MPNSTs (Table 3). For instance, a deletion on chromosome
4 was present in 6 of the 11 tumors; this region of chro-
mosomal loss (chr4: 88,934,158e89,039,587) contains the
Cdkn2a and Cdkn2b genes. A global examination of the
focal CNVs present in these P0-GGFb3 MPNSTs showed
that genes represented in the Atlas of Genetics and Cyto-
genetics in Oncology and Hematology, CANgenes, CIS, or658Sanger Cancer Gene Census databases were evident in 22
of the 44 regions; 13 were ampliﬁed and 9 were deleted
(Table 3). Overall, 39 genes previously implicated in the
pathogenesis of other human cancer types were identiﬁed
within these regions (one to eight genes per focal CNV).
The functions of the candidate cancer driver genes present
within focal CNVs in P0-GGFb3 MPNSTs were varied, and
affected multiple processes relevant to tumorigenesis
(Table 4). A number of the affected loci encode proteins thatajp.amjpathol.org - The American Journal of Pathology
Figure 9 aCGH analysis of a 488-kb region in chromosome 11 that surrounds a region of relative copy number loss present in two P0-GGFb3 MPNSTs (A202
and B76). The genomic map indicates the location of the genes present within the region illustrated in the accompanying panels, which indicate the relative
signals in tumor (red) and non-neoplastic Schwann cell (green) DNAs in the MPNSTs. The height of the colored bar indicates the relative difference in these two
signals. Note the central 44-kb region in which there is a relative copy number loss in these two MPNSTs.
Mouse Model of NFeMPNST Progressioncontrol proliferation (Myc,Tpd52, Strn; all ampliﬁed), the cell
cycle (Cdkn2a, Cdkn2b, Chfr, Chek2, Cdk2ap1, Cdk4), and
chromatin remodeling (Ep400). Several genes regulating
apoptosis (Bbc3/PUMA, Ddit3/GADD153, XIAP) were also
present within focal areas of unbalanced gain or loss. Genes
were identiﬁed that encode molecules in key cytoplasmic
signaling pathways, including the Hippo (Stk4), NotchFigure 10 Ideogram indicating the locations of focal CNVs detected by
aCGH data in early-passage cultures established from P0-GGFb3 MPNSTs.
Regions of copy number gain are indicated in red, and regions of unbal-
anced loss are indicated in green. The lengths of the red and green bars are
proportional to the size of the CNV.
The American Journal of Pathology - ajp.amjpathol.org(Dtx3), Hedgehog (Gli1), Arf (Agap2), Rho (Arhgap9), PI3
kinase (Pten), and Myc (Myc) pathways; also affected were
genes for growth factors, cytokines, and growth factor
receptors potentially upstream of some of these signaling
cascades (Ghr, Il17a, Inhbe). Other candidate cancer driver
genes within these small CNVs function in key metabo-
lic pathways (Aldob, Mars, Alad), transcriptional control
(Ncoa3, Nr4a3, Zscan22), vesicular trafﬁcking (Napa), and
cell motility (Sept6, Vcl).
It was also notable, however, that some small CNVs that
did not contain genes previously implicated in the patho-
genesis of any tumor type were repeatedly identiﬁed in
P0-GGFb3 MPNSTs (Table 3). The most common of these
CNVs was a region of copy number gain on chromosome
4 (chr4: 111,745,189e112,130,291) that was present in 10/11
tumors examined. This region contains three genes (Skint4,
Skint3, and Skint9) with poorly understood function; Skint1,
the prototypic member of this group of molecules, has been
implicated in the maturation of epidermal gd T cells.66 Other
recurrent CNVs lacking genes previously implicated in the
pathogenesis of human cancers included a region of deletion
on chromosome 17 that occurred in 5/11 tumors (chr17:
30,714,112e31,047,626, encompassing Glo1, Dnahc8,
AK018977, and Glp1R), a focal gain on chromosome 14 that
was present in 5/11 tumors (chr14: 69,877,095e69,987,156,
encompassing Slc25a37 and Entpd4), and a small deletion
on chromosome 1 that was evident in ﬁve tumors (chr1:
173,444,742e173,494,144, encompassing Itln1 andCd244).
Considered together, these observations suggest that several
of the relatively small regions of chromosomal copy number
gain or loss evident in P0-GGFb3MPNSTs contain important
driver genes that have not been previously implicated in
carcinogenesis.659
Table 3 Genes within Small and Minimal Critical Regions of Gain or Loss in P0-GGFb3 MPNSTs
Minimal critical region Gain or loss Cell lines Genes
Chromosome 1
18,123,973e20,989,757 Gain A18 Crisp4, Defb18, Defb49, Defb41, Gm15386, Tcfap2 days, Tcfap2b,
Pkhd1, Mir206, Il17a, Il17f, AK205147, Mcm3, Paqr8, Efhc1
172,530,936e172,637,996 Loss A390 Olfm12b, Atf6
173,444,742e173,494,144 Loss A292, B96, B91, B86, B76 BC145376, Itln1, Cd244
Chromosome 2
27,740,854e27,893,558 Gain A202 Col15a1, BC152372
85,976,236e86,076,234 Gain A231Tr Olfr1040, Olfr1042, Olfr1043, Olfr1044, Olfr52, Olfr1045,
Olfr1046, Olfr1047, Olfr1048
86,061,726e86,087,429 Loss A202, A18 Olfr1047, Olfr1048
118,994,902e119,055,137 Loss A18 Gchfr, Dnajc17, Gm14137, Zfyve19, Ppp1r14 days
163,824,466e163,964,059 Loss A18 Ywhab, Pabpc1l, 1810053B01Rik, Tomm34, Stk4
165,860,752e165,971,779 Loss A18 Ncoa3, Sulf2
Chromosome 3
8,919,417e9,605,520 Gain A202 Mrps28, Tpd52, AK016002, Zbtb10, C030034L19Rik, Zfp704
Chromosome 4
47,961,806e52,868,964 Loss A390 AK133250, Nr4a3, Stx17, Erp44, Invs, Tex10, 5730528L13Rik,
Tmeff1, Murc, E130309F12Rik, Acnat2, Acnat1, AK018513, Baat,
Mrp150, Aldob, Zfp189, Rnf20, Ppp3r2, 2810432L12Rik, Grin3a,
Cylc2, S60135, S60130, AK012547, Smc2, 4930547C10Rik,
Olfr275
62,162,092e62,182,694 Gain A231Tr, A202, A18, A390 Hdhd3, Alad
88,168,201e88,829,428 Loss A382 Ifnb1, Gm12597, Ifna14, Ifna9, Ifna12, C87499, Ifna13,
Gm13280, Ifna2, Ifnab, Klh19, Gm13271, Gm13285, Gm13276,
Ifnz, Gm13275, Gm13287, Ifna7, Ifna11, Ifna6, Ifna5, Ifna4,
Ifna1, Ifn3, Mir31, AK144962, Gm12603, Mtap
88,934,158e89,039,587 Loss A231Tr, B96, B91, B86,
A382, A292
Cdkn2a, AK148321, Cdkn2b
98,831,785e99,056,334 Gain A202 Atg4c
111,745,189e112,130,291 Gain A231Tr, B96, B91, B86, B76,
A394, A382, A292,
A202, A390
Skint4, Skint3, Skint9
Chromosome 5
110,540,802e111,792,099 Gain A202 Zfp605, Chfr, AK053084, Golga3, Ankle2, Pgam5, Pxmp2, Pole,
P2rx2, Gm1679, Fbrsl1, 2410025L10Rik, AK088579, AK041600,
Galnt9, Ddx51, Ep400, Noc4l, AK044789, Pus1, Ulk1, Hscb,
Chek2, Ttc28, Mir701, Pitpnb, AK039279
124,704,754e124,838,557 Loss A18 Mphosph9, 281006K23Rik, Cdk2ap1, Sbno1
Chromosome 7
12,807,582e14,904,447 Gain A18 Vmn1r81, Vmn1r82, Vmn1r83, Vmn1r84, Zfp551, Zfp606,
290092C05Rik, Vmn2r53, Vmn2r54, Vmn2r55, Vmn2r56, Zscan18,
Zfp329, Zfp110, Zfp128, Zscan22, Rp25, Zfp324,
2310014L17Rik, Zfp446, Zbtb45, Slc27a5, Trim28, Chmp2a,
Ube2m, Mzf1, Vmn1r86, Vmn1r85, Vmn1r87, Vmn1r88, Vmn1r89,
6330408A02Rik, AK132923, Lig1, Pla2g4c, Cabp5, Bsph1,
9230107M04Rik, Bsph2, Sult2a5, Sult2a2, Sult2a1, Sult2a4,
Sult2a3, Sult2a6, EG629219
16,685,001e17,087,560 Loss A18 Napa, Kptn, Slc8a2, Meis3, mKIAA0134, Dhx34, Gpr77, C5ar1,
Prr24, Ccdc9, Bbc3, Sae1, Zc3h4, Tmem160, Npas1, Grlf1
19,998,996e20,191,762 Gain B76 Ckm, AK020867, mKIAA1860, Mark4, Exoc312, Bloc1s3,
Trappc6a, Nkpd1, Lrrc68, AK195979, Gemin7, Zfp296, Sfrs16,
Clasrp, Rel
54,644,122e54,885,354 Gain B86 Mrgpra2a, Mrgpra2b, Mrgpra3
123,174,938e123,176,223 Loss A292, A382 Sox6
Chromosome 9
103,906,930e103,968,229 Gain A18 Nphp3, Uba5, Acad11
Chromosome 10
80,128,600e80,381,401 Loss A394, B91 Mknk2, Mnk2, Mobkl2a, Izumo4, Ap3d1, Dot1l, Plekhj1, Sf3a2,
Amh, Jsrp1, Oaz1, Mir1982, AK087942, Lingo3, Lsm7,
3110056O03Rik, Spp12b, Tmprss9, Timm13, Lmnb2
(table continues)
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Table 3 (continued )
Minimal critical region Gain or loss Cell lines Genes
80,993,669e83,063,521 Gain B76 Gna11, Aes, Tle2, Tle6, Sirt6, BC025920, Ankrd24, Gm10778,
BC064812, Zfp781, AK136722, BC062115, Zfp873, AU041133,
B230315N10Rik, Mif1, Gm1553, 1190007I07Rik, Tdg, Glt8d2,
Hcfc2, Nfyb, AK006461, Txnrd1, Eid3, Chst11, Slc41a2,
D10Wsu102e, Aldh1l2, Appl
93,173,564e93,303,322 Gain A202 Ntn4, AK145310, DQ556351, Usp44
125,404,179e127,428,204 Gain A18 Lrig3, AK005576, Xrcc6bp1, AK087024, Ctdsp2, Mir26a-2, Mir546,
Avil, Tsfm, Mettl1, Cyp27b1, Cdk4, Tspan31, March9, Agap2, Os9,
B4galnt1, Slc26a10, Arhgef25, Dtx3, Deltex3, AK077682,
Pip4k2c, Kif5a, Dctn2, Mbd6, Ddit3, Mars, Arhgap9, Gli1, Inhbe,
Inhbc, R3hdm2, Stac3, Ndufa4l2, Shmt2, Nxph4, Lrp1, Stat6,
Nab2, BC029853, AK005897, Tmem194, Myo1a, Tac2, Zbtb39,
Gpr182, Rdh1, Rdh9, Rdh16, Rdh18-ps, BC089597, Rdh7, Sdr9c7,
Hsd17
Chromosome 12
37,823,207e37,970,476 Loss A292 Meox2, Tmem195
115,837,534e117,190,767 Gain A202, A18 Antibody parts, X73024, AB345949
Chromosome 14
21,275,133e22,200,898 Loss A18 Anxa7, Zmynd17, Ppp3cb, 1810062O18Rik, Usp54, Myoz1,
Synpo2l, Sec24c, AK018074, AK204442, 6230400D17Rik,
2310021P13Rik, Kiaa0913, Ndst2, Camk2g, AK039280, Plau, Vcl,
Ap3m1, Adk
53,008,490e54,874,949 Gain B86 Olfr1511, Olfr1510, Tcra, Olfr1509, Olfr1508, Olfr1507,
Gm10886, AJ311366, X98059, Z22845, Gm13948, Gm10905,
X56719, D16605, Gm13960, Gm10895, Gm13980,
ENSMUSG000000836, Vdelta6.4, GM16979, GM13907, AK138453,
X02930, Gm10902, AK038197, EG547424, M21205, X56722,
X02969, Gm16460, Gm16979, Gm13907, U07879, Gm16980,
Gm13980, AK038197, EG547424, Gm17002, Gm13953,
Gm13948, Gm16452, M34214 and multiple TCR-alpha genes
69,877,095e69,987,156 Gain A390, B76, B86, B91, B96 Slc25a37, D930020E02Rik, AK046510, Entpd4, AK086749,
BC086315
Chromosome 15
3,228,882e4,824,497 Gain A390 Sepp1, Ccdc152, Ghr, Fbxo4, AW549877, AK041537, BC037032,
Oxct1, AK028088, Plcxd3, C6
60,562,187e62,065,471 Gain A202, A390 Fam84b, 9930014A18Rik, DQ715236, AK015045, A1bg,
EU234017, AK163289, AK132958, Myc, Pvt1, H2afy2
71,284,106e72,565,945 Gain A390 Fam135b, Col22a1, Kcnk9, Trappc9
Chromosome 16
43,620,829e43,773,291 Gain B76 Zbtb20, AK038731, Mir568, Tigit, Drd3
Chromosome 17
30,714,112e31,047,626 Loss A231Tr, A202, B86,
A390, A382
Glo1, Dnahc8, AK018977, Glp1r
79,124,627e79,148,417 Gain B91 Strn
Chromosome 19
32,866,825e32,944,421 Loss A202 Pten, B430203M17Rik
Chromosome X
7,276,714e7,415,340 Gain A394 Gpkow, Wdr45, Praf2, Ccdc120, Mir684-1, Tcfe3, Gripap1, Kcnd1
34,183,857e34,755,807 Gain B76 Akap17b, Slc25a43, Slc25a5, C330007P06Rik, Ube2a, Nkrf,
Sept6, Ankrd58, Rp139, Snora69, Upf3b, Nkap, Akap14, Ndufa1,
Rnf113a1, Gm9, Rhox1
39,447,121e40,770,156 Loss A292 Xiap, Stag2, Xlp, Sh2d1a, Odz1, Ten-m1
153,911,519e153,991,073 Gain A202 Sms, Mbtps2
Cancer driver genes represented in the Atlas of Genetics and Cytogenetics in Oncology and Haematology, CANgenes, CIS, and/or Sanger Cancer Gene Census
databases are highlighted with boldface and underlining.
Mouse Model of NFeMPNST ProgressionDiscussion
We have previously shown that the NRG1/ErbB signaling
pathway is constitutively activated in human neuroﬁbromasThe American Journal of Pathology - ajp.amjpathol.organd MPNSTs,40 that this pathway promotes the proliferation
and migration of neoplastic Schwann cells isolated from
these human tumors,39,40 and that transgenic mice express-
ing the NRG1 isoform GGFb3 in Schwann cells develop661
Table 4 Functions of Candidate Driver Mouse Genes in Small Regions of Unbalanced Gain and Loss
Gene
symbol Gene name Function
Pkhd1 polycystic kidney and hepatic disease 1 Cilium assembly, centrosome duplication
Il17a interleukin 17A Inflammatory response
Stk4 serine/threonine kinase 4 Hippo signaling cascade
Ncoa3 nuclear receptor coactivator 3 Ligand-dependent transcription factor
Sulf2 sulfatase 2 Extracellular sulfatase
Tpd52 tumor protein D52 Promotes proliferation, survival and metastasis;
regulates lysosomal trafficking
Nr4a3 nuclear receptor subfamily 4, group A, member 3 Ligand-dependent transcription factor
Aldob aldolase B, fructose-biphosphate Glycolysis
Alad aminolevulinate, delta-, dehydratase Heme biosynthesis
Cdkn2a cyclin-dependent kinase inhibitor 2A Cell cycle arrest
Cdkn2b cyclin-dependent kinase inhibitor 2B Cell cycle arrest
Chfr checkpoint with forkhead and ring finger domains Mitotic checkpoint protein, maintains chromosome
integrity
Ep400 E1A binding protein p400 (syn. mDomino) ATP-dependent chromatin-remodeling protein
Chek2 checkpoint kinase 2 (syn. Rad53) DNA damage checkpoint control
Cdk2ap1 CDK2 (cyclin-dependent kinase 2)-associated protein 1 Negative regulator of Cdk2 function
Sbno1 strawberry notch homolog 1 (Drosophila) Unknown
Zscan22 zinc finger and SCAN domain containing 22 GlieKruppel family transcription factor
Napa N-ethylmaleimide sensitive fusion protein attachment
protein alpha
Trans-Golgi vesicle trafficking
Bbc3 Bcl2 binding component 3 (syn. PUMA) p53-regulated inducer of apoptosis
Mark4 MAP/microtubule affinity-regulating kinase 4 Serine-threonine kinase
Gna11 guanine nucleotide binding protein, alpha 11 G-protein coupled receptor signaling mediator
Zfp873 zinc finger protein 873 Unknown
Cdk4 cyclin-dependent kinase 4 Cell cycle progression
Agap2 ArfGAP with GTPase domain, ankyrin repeat and PH
domain 2
Regulator of ARF activity
Dtx3 deltex 3 homolog (Drosophila) Notch signaling pathway
Ddit3 DNA damage-inducible transcript 3 (syn. GADD153,
CHOP10)
Promotes cell cycle arrest, macroautophagy
Mars methionine-tRNA synthetase Charges Met-tRNA with methionine
Arhgap9 Rho GTPase activating protein 9 Inactivates Rho signaling
Gli1 GLI-Kruppel family member GLI1 Transcription factor that promotes proliferation,
Hedgehog signaling pathway
Inhbe inhibin beta E (syn. activin, activin betaE) Growth factor
Vcl vinculin Adherens junction component, modulates focal
adhesion
Tcra T cell receptor alpha chain (gene cluster) Antigen recognition
Ghr growth hormone receptor Growth hormone receptor
Myc myelocytomatosis oncogene Nuclear phosphoprotein regulating cell cycle
progression, apoptosis and transformation
Pvt1 plasmacytoma variant translocation 1 Encodes multiple miRNAs
Strn striatin, calmodulin binding protein Cytoplasmic signaling molecule, inhibits proliferation
Pten phosphatase and tensin homolog Inhibits PI3 kinase activity
Sept6 septin 6 Cytoskeleton, regulates motility
Xiap X-linked inhibitor of apoptosis Inhibits apoptosis
syn., synonym.
Kazmi et alMPNSTs.41 Building on these earlier ﬁndings, in the present
study we have demonstrated that P0-GGFb3 mice develop
large numbers of neuroﬁbromas and that these lesions
potentially progress to become MPNSTs at a high
frequency. This suggests that neuroﬁbromaeMPNST
progression in P0-GGFb3 mice, in contrast to that in Nf1
knockout models, occurs commonly and recapitulates the662pathological process seen in human NF1. Furthermore, the
molecular abnormalities evident in P0-GGFb3 MPNSTs,
which include Ras hyperactivation and defects in the
p19ARFeMdmep53, p16INK4Aecyclin D/CDK4eRb, and
p27Kip1/CDK2 pathways, parallel the alterations often
encountered in human MPNSTs. These ﬁndings led us to
hypothesize that P0-GGFb3 mice could be used to identifyajp.amjpathol.org - The American Journal of Pathology
Mouse Model of NFeMPNST Progressionpreviously unknown driver genes mediating neuroﬁbroma
pathogenesis and the subsequent progression of these
tumors to become MPNSTs. Consistent with this postulate,
our aCGH studies identiﬁed multiple chromosomal gains
and losses that affected a number of driver genes that had
been previously implicated in the pathogenesis of other
types of human cancers, but not in MPNSTs. We also
identiﬁed several recurrent CNVs that affected genes that
have never been implicated in the pathogenesis of any type
of human cancer, suggesting that P0-GGFb3 mice can be
useful for the identiﬁcation of previously unknown driver
genes with novel mechanisms of action.
More than 90% of the P0-GGFb3 mice that we studied
developed multiple low-grade nerve sheath tumors with
histological and immunohistochemical features identical to
those of human neuroﬁbromas. Our previous necropsy
examinations of younger (0 to 4 months old) P0-GGFb3
mice showed no evidence of such lesions,41 which indicates
that these neuroﬁbromas are not congenital, but instead
develop later in life. This delay in the development of
neuroﬁbromas, along with the fact that a small percentage of
P0-GGFb3 mice do not develop neuroﬁbromas, implies that
GGFb3 overexpression alone is not sufﬁcient for the path-
ogenesis of these benign neoplasms and that additional
abnormalities, such as the mutation of as yet unknown
driver genes, are required for their development. Conse-
quently, P0-GGFb3 mice can be a useful model system for
identifying novel driver genes mediating neuroﬁbroma
pathogenesis.
In addition, the distribution of neuroﬁbromas in P0-
GGFb3 mice raises interesting questions about the origin of
these tumors. We observed that neuroﬁbromas arising in P0-
GGFb3 mice typically develop within ganglia associated
with sensory (spinal dorsal nerve root), sympathetic (celiac,
superior mesenteric, and superior cervical ganglia), and
motor (trigeminal) nerves. This suggests that neuroﬁbroma
development within ganglia in P0-GGFb3 mice is a result of
these neoplasms being derived from a progenitor intrinsic to
these structures, or that it occurs because the intraganglionic
microenvironment is particularly conducive to tumorigen-
esis. Of note, embryonic dorsal root ganglia have been
shown to contain a progenitor pool that expands and
becomes hypersensitive to growth factors after Nf1 loss, and
it has been proposed that neuroﬁbromas may be derived
from these progenitors.67 Further studies would be war-
ranted to determine whether NRG1 overexpression similarly
expands this intraganglionic progenitor pool, whether these
cells give rise to neuroﬁbromas in P0-GGFb3 mice, and
whether the expansion of this progenitor pool and subse-
quent neuroﬁbroma pathogenesis in Nf1 knockout models is
also dependent on NRG1 signaling.
MPNSTs were also present in P0-GGFb3 mice carrying
multiple neuroﬁbromas but the MPNSTs most often
occurred as single lesions. Furthermore, we noted that some
neuroﬁbromas contained microscopic foci morphologically
identical to the MPNSTs that we found in these animals.The American Journal of Pathology - ajp.amjpathol.orgConsidered together, these ﬁndings suggest that MPNSTs
arise via progression from pre-existing neuroﬁbromas in P0-
GGFb3 mice, much as is seen in human NF1. The molec-
ular abnormalities present in P0-GGFb3 MPNSTs also
largely parallel those typically seen in their human coun-
terparts. We did not ﬁnd evidence of a loss of neuroﬁbromin
protein or Nf1 mRNA in all of our MPNSTs. Although these
initial studies did not exclude the possibility that point
mutations might be present in the Nf1 transcripts expressed
in P0-GGFb3 MPNSTs, we have since performed RNA-Seq
high-throughput sequencing on two of these sarcomas and
found no evidence of Nf1 mutations (data not shown). The
absence of Nf1 mutations but continued neuroﬁbromin
expression in P0-GGFb3 MPNSTs raises the question of
whether the sarcomas seen in these mice are analogous to
human sporadic MPNSTs, at least some of which lack
NF1 mutations.10 However, we also found that Ras proteins,
which are negatively regulated by neuroﬁbromin, are
hyperactivated in P0-GGFb3 MPNSTs, indicating that these
tumors demonstrate the biochemical abnormality classically
associated with neuroﬁbromin loss. Consequently, these
ﬁndings argue that class II NRG1 overexpression results in
neuroﬁbroma and MPNST pathogenesis, because this
growth factor acts largely within the same biochemical
pathways that are affected by NF1 loss. Furthermore,
disruption of the p16INK4Aecyclin D/CDK4eRb pathway
was evident in every P0-GGFb3 MPNST we examined. Lost
or diminished Cdkn2a expression, which often correlated
with copy number loss affecting this locus, was particularly
common, occurring in 72% (13/18) of the MPNSTs. This
parallels observations in human MPNSTs, where 50% to
86% of these tumors have been shown to have CDKN2A
loss.51,52,55
Our ﬁnding that 33% (6/18) of P0-GGFb3 MPNSTs
demonstrate abnormal p53 expression or mutation is also
consistent with multiple earlier studies demonstrating that
p53 abnormalities are present in a major subset of human
MPNSTs.11,12,48,49,58 Mdm2 overexpression, which we
found in 17% of the P0-GGFb3 MPNSTs we examined, is
likewise present in 20% to 25% of human MPNSTs.48,68 To
our knowledge, the possibility that Mdm4 is overexpressed
in human MPNSTs has not yet been examined. Finally,
p27Kip1 abnormalities, which we identiﬁed in P0-GGFb
MPNSTs, have also been identiﬁed in human MPNSTs.58
Considered together, this pathological and molecular evi-
dence indicates that tumorigenesis in the peripheral nervous
system of P0-GGFb3 mice occurs via a process that is
highly similar to that operant in human NF1.
Mouse cancer models can greatly facilitate the rapid
identiﬁcation of driver mutations relevant to the pathogenesis
of their human counterpart. In part, this advantage is due to
intrinsic differences in the stability of human and mouse
cancer genomes.69 Human cancer genomes are usually
structurally complex, with numerous regions of focal chro-
mosomal gain and loss; however, only a small subset of these
focal chromosomal gains and losses contain cancer driver663
Kazmi et algenes (genes that promote cancer pathogenesis), with the
remainder resulting in passenger mutations (mutations that do
not confer an advantage on the tumor cells). In contrast,
mouse cancer genomes have relatively few structural abnor-
malities; they tend rather to have whole chromosome gains or
losses, with a much more limited number of focal gains and
losses. These patterns are borne out in both human MPNSTs
and the MPNSTs that arise in P0-GGFb3 mice. Human
MPNSTs have complex hypodiploid or near-triploid karyo-
types, with numerous and highly diverse regions of chro-
mosomal gain or loss.15e22,70,71 However, our aCGH studies
revealed a more restricted set of chromosomal abnormalities
in the MPNSTs that arose in P0-GGFb3 mice, with whole
chromosome or whole chromosome arm CNVs being
particularly common. The whole chromosome gains and
losses evident in these mouse cancer genomes were not
random, because some events occurred repeatedly. Of
particular note, copy number gains affecting chromosome 11
were uniformly present in all 18 MPNSTs. Mouse chromo-
some 11 contains regions that are syntenic with segments of
human chromosomes 1, 2, 5, 7, 16, 17, and 22. Although
comparative genomic hybridization analyses of human
MPNSTs have not identiﬁedCNVs affecting chromosomes 1,
2, 5, 16, or 22, gains affecting the short arm of chromosome
7 (7p) and the long arm of chromosome 17 (17q) are repro-
ducibly present in human MPNSTs.20,21,72,73 Although the
region on chromosome 7p that is affected in humanMPNSTs
is not syntenic with mouse chromosome 11, the 17q amplicon
occurring in human MPNSTs is syntenic with mouse chro-
mosome 11. Genes within this region of copy number gain
that have been suggested to potentially promote neuro-
ﬁbromaeMPNST progression in humans include BIRC5/
survivin, ERBB2, TOP2A, PTDSR/Jmjd6, SEPT9, and
SOSC3.73 Going forward, it should be of great interest to
establish the functional signiﬁcance of these genes in human
and mouse MPNST pathogenesis and to determine whether
there are additional genes on mouse chromosome 11 that
promote MPNST pathogenesis.
The intrinsic stability of mouse cancer genomes also
ensures that those focal gains or losses that do occur in these
tumors arise as a result of strong selective pressure; this
selective pressure often reﬂects the presence of a driver gene
in the affected interval.18 Moreover, because key driver
genes (and their associated pathways) are usually evolution-
arily conserved, driver genes within focal CNVs occurring in
mouse cancers are potentially relevant to the pathogenesis of
their human counterparts. We identiﬁed a total of 44 focal
gains and losses in the 18 P0-GGFb3 MPNSTs; this limited
number of focal CNVs affected 39 genes that had previously
been implicated in the pathogenesis of human cancer types
other than MPNSTs. Several of these CNVs occurred in
multiple tumors, emphasizing their importance to the patho-
genesis of P0-GGFb3MPNSTs. Other CNVs, however, were
less common, with some identiﬁed on only a single MPNST.
This does not mean that these rarer CNVs are irrelevant to
MPNST pathogenesis, because at least some of these gains664and losses affected genes that have already been linked to the
development of MPNSTs. For instance, we found a focal loss
on chromosome 19 (chr19; 32,866,825e32,944,421) in only
one of the tumors we examined with aCGH; however, this
loss affected the Pten tumor suppressor gene, which has been
implicated in the pathogenesis of human MPNSTs74,75 and
which, when deleted in the setting of K-Ras activation, leads
to MPNST pathogenesis in genetically engineered mice.75
Consequently, further studies are warranted, performing
aCGH on a larger series of P0-GGFb3 MPNSTs to identify
additional focal CNVs relevant to MPNST pathogenesis,
determine how frequently each of these focal gains and losses
occur, and investigate whether speciﬁc gains and losses are
also associated with distinct molecular subtypes of MPNSTs.
To date, only NF1 loss has been implicated in the devel-
opment of neuroﬁbromas, whereas studies of the genes
responsible for neuroﬁbromaeMPNST progression have
focused almost exclusively on proteins within cell-cycle
regulatory pathways. Although we identiﬁed abnormalities in
these same molecules in P0-GGFb3 MPNSTs, our aCGH
ﬁndings suggest that abnormalities affecting a much more
diverse variety of cellular functions also occur in these
sarcomas. Potentially affected functions include proliferative
signaling (eg, Stk4,Tpd52,Agap2,Gna11,Dtx3), transcription
(eg, Ncoa3, Gli1), tumor cell survival (eg, Xiap, Bbc3, Ddit3),
cytoskeletal structure and motility (eg, Vcl, Sept6), immune
function (eg, Il17a), and metabolism (eg, Aldob, Alad,Mars).
The occurrence of abnormalities affecting a variety of cellular
functions in P0-GGFb3 MPNSTs is consistent with observa-
tions in numerous other human cancer types.70 However, the
observation that some recurrent focal gains and losses did not
contain any genes previously implicated in the pathogenesis of
other human cancer types is evenmore intriguing, because this
suggests that these intervals may contain novel driver genes. In
future studies, it would be of great interest to identify these
novel driver genes, establish their mechanism of action, and
determine whether they are similarly affected in human
neuroﬁbromas and/or MPNSTs. Having said that, we also
emphasize that the abnormalities that we have detected with
aCGH likely represent only a subset of the abnormalities
driving the pathogenesis of peripheral nerve sheath tumors in
P0-GGFb3 mice. This is because aCGH analyses identify
relatively large CNVs and do not detect some quite common
types ofmutations that are highly relevant to tumorigenesis (eg,
relatively small deletions, frameshift mutations, missense
mutations, and nonsense mutations). Approaches such as
sequencing the transcriptome and the exomewould be required
to identify these latter types of mutations.
In summary, we have shown that the vast majority of
transgenic mice overexpressing the NRG1 isoform GGFb3 in
Schwann cells develop numerous neuroﬁbromas and smaller
numbers ofMPNSTswhich potentially arise frompre-existing
neuroﬁbromas. These observations, considered together with
our ﬁnding that molecular abnormalities occurring in human
neuroﬁbromas and MPNSTs are present also in P0-GGFb3
MPNSTs, argue that P0-GGFb3mice appropriately model theajp.amjpathol.org - The American Journal of Pathology
Mouse Model of NFeMPNST Progressionprocess of neuroﬁbromaeMPNST progression seen in human
NF1. A number of previous reports have commented on the
fact that chromosomal gains and losses are highly variable in
human MPNSTs and that tumor suppressors such as p53 are
not uniformly mutated in these neoplasms.2 These observa-
tions suggest that theremay bemore than one pathway leading
to MPNST pathogenesis. Because neuroﬁbroma and MPNST
formation in P0-GGFb3 mice results from growth factor
overexpression (rather than from ablation of speciﬁc tumor
suppressor genes), tumorigenesis in these animals, unlike in
previous knockoutmodels, is not necessarily dependent on the
mutation of a restricted collection of tumor suppressors; this
suggestion is consistent with our observation that key tumor
suppressor mutations (eg, p53) and focal CNVs were variably
present in P0-GGFb3 MPNSTs. Consequently, P0-GGFb3
mice represent a novel model system that could be used
to identify alternative pathways mediating neuroﬁbromae
MPNST progression. We intend to conduct future studies
directed toward expanding our aCGH experiments to include
a larger cohort of P0-GGFb3 neuroﬁbromas andMPNSTs and
examining these neoplasms with additional approaches, such
as RNA-Seq and exome sequencing, so that more subtle
mutations promoting peripheral nervous system tumorigen-
esis can be identiﬁed and considered as potential therapeutic
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